Targeting Splicing in the Treatment of Human Disease
AbstractThe tightly regulated process of precursor messenger RNA (pre-mRNA) alternative splicing (AS) is a key mechanism in the regulation of gene expression. Defects in this regulatory process affect cellular functions and are the cause of many human diseases. Recent advances in our understanding of splicing regulation have led to the development of new tools for manipulating splicing for therapeutic purposes. Several tools, including antisense oligonucleotides and trans-splicing, have been developed to target and alter splicing to correct misregulated gene expression or to modulate transcript isoform levels. At present, deregulated AS is recognized as an important area for therapeutic intervention. Here, we summarize the major hallmarks of the splicing process, the clinical implications that arise from alterations in this process, and the current tools that can be used to deliver, target, and correct deficiencies of this key pre-mRNA processing event. View Full-Text
Share & Cite This Article
Suñé-Pou, M.; Prieto-Sánchez, S.; Boyero-Corral, S.; Moreno-Castro, C.; El Yousfi, Y.; Suñé-Negre, J.M.; Hernández-Munain, C.; Suñé, C. Targeting Splicing in the Treatment of Human Disease. Genes 2017, 8, 87.
Suñé-Pou M, Prieto-Sánchez S, Boyero-Corral S, Moreno-Castro C, El Yousfi Y, Suñé-Negre JM, Hernández-Munain C, Suñé C. Targeting Splicing in the Treatment of Human Disease. Genes. 2017; 8(3):87.Chicago/Turabian Style
Suñé-Pou, Marc; Prieto-Sánchez, Silvia; Boyero-Corral, Sofía; Moreno-Castro, Cristina; El Yousfi, Younes; Suñé-Negre, Josep M.; Hernández-Munain, Cristina; Suñé, Carlos. 2017. "Targeting Splicing in the Treatment of Human Disease." Genes 8, no. 3: 87.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.